

Appendix F – Regulation pertaining to PNA
supplementary statements.

The health and wellbeing board will also need to put in place a system which allows it to identify any changes to the availability of pharmaceutical services and then determine whether or not it needs to issue a supplementary statement. A supplementary statement is to be published to explain changes to the availability of pharmaceutical services where:

(a) the changes are relevant to the granting of an application or applications for inclusion in the pharmaceutical list for the area of the health and wellbeing board's area; and

(b) the health and wellbeing board is satisfied that producing a new pharmaceutical needs assessment would be a disproportionate response to those changes or it is already producing its next pharmaceutical needs assessment but is satisfied that it needs to immediately modify the existing document in order to prevent significant detriment to the provision of pharmaceutical services.

*Supplementary statements are statements of fact; they do not make any assessment of the impact the change may have on the need for pharmaceutical services. Effectively, they are an update of what the pharmaceutical needs assessment says about the availability of pharmaceutical services. **They are not a vehicle for updating what the pharmaceutical needs assessment says about the need for pharmaceutical services.***

The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013
UK Statutory Instruments 2013 No. 349 PART 2 Regulation 6
[The National Health Service \(Pharmaceutical and Local Pharmaceutical Services\) Regulations 2013
\(legislation.gov.uk\)](https://www.legislation.gov.uk)